Humanigen, Inc
HGENDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001293310
Humanigen, Inc was delisted in 2023; its insiders filed their last Form 4 on Oct 20, 2023; 38 institutions reported holding it in 13F filings for Q2 2023, worth $842.2K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 38
- Q2 2023, −4 vs. previous quarter
- 13F value
- $840.7K
- Reported value at the end of Q2 2023
- Superinvestors holding
- 0
- At the end of Q2 2023
Superinvestors holding HGEN, Q2 2023
No superinvestor reported holding HGEN at the end of Q2 2023.
Latest insider trades
Open-market purchases and sales by Humanigen, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2023 (view filing)6:50 PM ET | Oct 18 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −386.4K | $0.011 | −$4.25K | −4.4%8.40M after | 3 lots |
| May 20, 2022 (view filing)5:57 PM ET | May 18-20 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +1.04M | $2.17 | +$2.26M | +13.7%8.68M after | 9 lots |
| Mar 15, 2022 (view filing)6:23 PM ET | Mar 11 | 4 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +1.00M | $3.00 | +$3.00M | +14.4%7.94M after | 3 lots |
| Mar 14, 2022 (view filing) | Mar 8-9 | 6 daysLate | Kilcoyne AdrianChief Medical Officer | PPurchase | +12.0K | $2.63 | +$31.6K | New position12.0K after | 2 lots |
| Mar 10, 2022 (view filing)7:24 PM ET | Mar 8-10 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +468.5K | $0.01 | +$4.66K | –2.87K after | Derivative12 lots |
| Mar 4, 2022 (view filing)6:42 PM ET | Mar 2-4 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | PPurchaseCommon Stock, $0.001 par value | +996.8K | $0.0059 | +$5.87K | –5.69K after | Derivative15 lots |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Durrant CameronChief Executive Officer | PPurchase | +40.0K | $2.34 | +$93.6K | +133.3%70.0K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Jordan Edward P.Chief Commercial Officer | PPurchase | +12.5K | $2.32 | +$29.0K | New position12.5K after | |
| Aug 13, 2021 (view filing)9:28 PM ET | Aug 11-12 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −167.2K | $17.10 | −$2.86M | −2.2%7.27M after | 6 lots |
| Jul 30, 2021 (view filing)9:01 PM ET | Jul 28-29 | 2 days | Chappell Dale and 4 othersChief Scientific Officer | SSaleCommon Stock, $0.001 par value | −39.1K | $17.04 | −$665.9K | −0.5%7.37M after | 6 lots |
Top 10 13F holders, Q2 2023
The largest institutional positions in Humanigen, Inc at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,709,967 | $260.6K | 0.00% | +1,009,167+144.0% | Added |
| Bank of New York Mellon Corp | 878,331 | $133.9K | 0.00% | −6,102−0.7% | Reduced |
| Geode Capital Management, LLC | 861,958 | $131.4K | 0.00% | +379,595+78.7% | Added |
| BlackRock Inc. | 812,398 | $123.8K | 0.00% | −212,922−20.8% | Reduced |
| State Street Corp | 188,676 | $28.8K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 153,889 | $23.5K | 0.00% | −15,248−9.0% | Reduced |
| Two Sigma Securities, LLC | 152,136 | $23.2K | 0.00% | +99,659+189.9% | Added |
| Northern Trust Corp | 140,542 | $21.4K | 0.00% | 00.0% | Unchanged |
| Leonteq Securities AG | 100,000 | $15.2K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 62,003 | $9.45K | 0.00% | −1,211−1.9% | Reduced |